Two stocks in Healthcare
AstraZeneca vs Genus: profit, growth, debt and price compared
AstraZeneca is stronger on 4 of 7 figures: sales growth, price for its expected profit, dividend and price trend. Genus is stronger on 2: profit margin and debt.
Save both stocks to your watchlist and revisit their latest fundamentals.
| AstraZenecaAZN.L | GenusGNS.L | |
|---|---|---|
| Net margin | 17.7% | Stronger: 43.4% |
| Revenue growth, past year | Stronger: +6.70% | −4.10% |
| Debt to equity | 66.2% | Stronger: 14.0% |
| Forward P/E | Stronger: 16.1× | 18.5× |
| Dividend yield | Stronger: 1.73% | 1.56% |
| Analysts | Buy · 22 | Buy · 13 |
| From its 200-day average | Stronger: +5.0% | −7.1% |
Share price over the past year
- AstraZeneca0.0%
- Genus−14.3%
20 Nov 202518 Nov 2026
AstraZeneca or Genus: which is stronger?
- GNS.L
Which is more profitable?
Genus keeps more of each sale as profit: 43.4% against 17.7%.
- AZN.L
Which is growing its sales faster?
AstraZeneca is growing its sales faster: +6.70% over the past year, against −4.10%.
- GNS.L
Which has borrowed less?
Genus has borrowed less: its debt is 14.0% of what its shareholders own, against 66.2% for AstraZeneca.
- AZN.L
Which costs less for the profit it is expected to make?
AstraZeneca costs less for the profit it is expected to make: 16.1× its forward earnings, against 18.5×.
- AZN.L
Which pays more in dividends?
AstraZeneca pays more back in dividends for what a share costs: 1.73% a year, against 1.56%.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- AZN.L
Which is in the stronger price trend?
AstraZeneca's price is in the stronger trend: 5.0% above its 200-day average, against 7.1% below.
What each company does
AZN.LAstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Reports results on 9 February 2027
GNS.LGenus
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia.
Reports results on 25 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.